Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review

Journal of Geriatric Oncology

Volumn 2, Issue 1, 2011, Pages 64-71

  Francois E ^a   Guerin O ^b   Follana, P ^a   Evesque, L ^c   Mari, V ^a   Aparicio, T ^d  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b University of Côte d'Azur   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN;

ADVANCED CANCER; AGE DISTRIBUTION; AGED; AGING; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY DISEASE; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ELDERLY CARE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; VASCULAR DISEASE; VEIN DISEASE; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 78650417908     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2010.09.005     Document Type: Review

References (40)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44(10):1345-1389.
3. Chauvenet M., Lepage C., Jooste V., Cottet V., Faivre J., Bouvier A.M. Prevalence of patients with colorectal cancer requiring follow-up or active treatment. Eur J Cancer 2009, 45(8):1460-1465.
4. Latournerie M., Jooste V., Cottet V., Lepage C., Faivre J., Bouvier A.M. Epidemiology and prognosis of synchronous colorectal cancers. Brit J Surg 2008, 95(12):1528-1533.
5. Faivre J., Lemens V.E., Quipourt V., Bouvier A.M. Management and survival of colorectal cancer in the elderly in population-based studies. Eur J Cancer 2007, 43(15):2279-2284.
6. Bouché O., Castaing M., Etienne P.L., Texereau P., Auby D., Bedenne L., et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. J Clin Oncol 2007, 25(18S):a4069.
7. Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370(9582):135-142.
8. Seymour M.T., Maughan T.S., Ledermann J.A., Topham C., James R., Gwyther S.J., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370(9582):143-152.
9. Folprecht G., Cunningham D., Ross P., Glimelius B., Di Costanzo F., Wils J., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15(9):1330-1338.
10. Goldberg R., Tabah-Fisch I., Bleiberg H., de Gramont A., Tournigand C., Andre T., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administrated bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24(25):4085-4091.
11. E. Mitry, J.M. Phelip, F. Bonnetain, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis. 2008 Gastrointest Cancer Symposium; abstract 281.
12. Aparicio T., Desramé J., Lecomte T., Mitry E., Belloc J., Etienney I., et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003, 89:1439-1444.
13. François E., Berdah J.F., Chamorey E., Lesbats G., Teissier E., Codoul J.F., et al. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2008, 62(6):931-936.
14. Homsi J., Daud A. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14:285-294.
15. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
16. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
17. Frei C. Mc Kibbin, R. Greene, et al. Disparities in utilization of irinotecan, oxaliplatin and bevacizumab among young and elderly patients with advanced colorectal cancer. 2008 Gastrointest Cancers Symp 2008; (Abstr 358).
18. Saltz L.B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019.
19. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-1544.
20. Kabbinavar F.F., Schulz J., McCleod M., Patel T., Hamm J.T., Hecht J.R., et al. Addition of bevacizumab to bolus flurouracil and leucovorin in first-line metastatic colorectal cancer: results of randomized phase II trial. J Clin Oncol 2005, 23(16):3697-3705.
21. Kabbinavar F.F., Hurwitz H., Yi J., Sarkar S., Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009, 27(2):199-205.
22. Buyse M., Thirion P., Carlson R.W., Burzykowski T., Molenberghs G., Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378.
23. Cassidy J., Saltz L.B., Giantonio B.J., Kabbinavar F.F., Hurwitz H.I., Rohr U.P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010, 136:737-743.
24. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., DiBartolomeo M., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009 Nov, 20(11):1842-1847.
25. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., DiBartolomeo M., et al. Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BEAT observational cohort study. Eur J Cancer Suppl 2009, 7(2):349. (Abstr 6088).
26. Kozloff M., Yood M.U., Berlin J., Flynn P.J., Kabbinavar F.F., Purdie D.M., et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009, 14(9):862-870.
27. M. Kozloff, M. Sugrue, J. Berlin, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE Prospective Cohort Study. 2008 Gastrointestinal Cancers Symposium 2008, (Abstr 454).
28. E. Kubala, J. Bartos, L.B. Petruzelka, et al. Safety and effectiveness of bevacizumab (bev) in combination with chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from a large Czech Observational Registry (CSTP). Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2010, abstract 467.
29. Puthillath A., Mashtare T., Wilding G., Khushalani N., Steinbrenner L., Ross M.E., et al. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 2009, 71(3):242-248.
30. Feliu J., Safont M.J., Salud A., Losa F., García-Girón C., Bosch C., et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010 May 11, 102(10):1468-1473.
31. Vrdoljak E., Omrcen T., Hrabar A. Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer. J Clin Oncol 2009, 27. (suppl; abstr e15074).
32. A. Naeim, R. Lin, R. Dichmann, et al. Phase II study of front-line capecitabine and bevacizumab in frail and elderly patients with metastatic colorectal cancer. 2010 Gastrointestinal Cancers Symposium, (Abstr 340).
33. Fuchs C.S., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidynes in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007, 25(30):4779-4786.
34. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Colangelo L.H., Lopa S.H., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27:3385-3390.
35. Ranpura V., Hapani S., Chuang J., Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010 Apr, 49(3):287-297.
36. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
37. Raman A.K., Lombardo J.C., Chandrasekhar R., Fakih M.G. Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol 2007, 25. (suppl; abstr 14546).
38. Elice F., Jacoub J., Rickles F.R., Falanga A., Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 2008, 83:862-870.
39. Figer A., Perez-Staub N., Carola E., Tournigand C., Lledo G., Flesch M., et al. FOLFOX in patients aged between 76 and 80years with metastatic colorectal cancer. Cancer 2007, 110:2666-2671.
40. Schrag D., Cramer L.D., Bach P.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93(11):850-857.